

## Supporting information

Kuo MJ, Mo LR, Chen CL. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: The role of surgical or nonsurgical methods

**Table S1** Overall and tumor and liver reserve-specific relative hazards of disease-free survival and overall survival of HCC after curative treatment in association with treatment modalities with SR as reference strategy

**Figure S1** Comparison of survival curves of the patients with HCC in Barcelona Clinic Liver Cancer (BCLC) stage A HCC who underwent RFA-TACE or SR. (A) Cumulative OS curves of patients with HCC in BCLC A stage who underwent RFA-TACE and patients who underwent SR. (B) Cumulative DFS curves of patients with HCC in BCLC A stage who underwent RFA-TACE and patients who underwent SR. (C) After propensity score matching, the cumulative OS curves of patients with HCC in BCLC A stage who underwent RFA-TACE and patients who underwent SR. (D) After propensity score matching, the cumulative DFS curves of patients with HCC in BCLC A stage who underwent RFA-TACE and patients who underwent SR.

**Table S1** Overall and tumor and liver reserve- specific relative hazards of disease-free survival and overall survival of HCC after curative treatment in association with treatment modalities with SR as reference strategy

Size and number	No. of patients	Disease-free survival		Overall survival	
	RFA-TACE/SR	Crude HR (95% CI)	Adjusted HR* (95% CI)	Crude HR (95% CI)	Adjusted HR* (95% CI)
<b>Size</b>					
<3 cm	129/50	1.75(1.14-2.68)	1.49(0.95-2.35)	1.20(0.64-2.25)	1.08(0.53-2.17)
≥3cm	47/75	1.35(0.84-2.17)	1.01(0.61-1.68)	1.39(0.73-2.65)	1.12(0.55-2.26)
<b>Number</b>					
Single	126/104	1.50(1.06-2.13)	1.37(0.94-1.98)	1.40(0.85-2.31)	1.38(0.79-2.39)
Multinodularity	50/21	1.29(0.70-2.37)	1.09(0.55-2.13)	0.74(0.31-1.76)	0.72(0.26-1.96)
<b>Staging</b>					
BCLC 0	47/18	1.12(0.54-2.30)	1.09(0.50-2.36)	1.12(0.30-4.21)	1.03(0.26-4.05)
BCLC A	129/107	1.77(1.27-2.46)	1.58(1.12-2.22)	1.37(0.88-2.15)	1.30(0.81-2.08)
<b>CSPH</b>					
No	131/99	1.61(1.13-2.29)	1.23(0.83-1.82)	1.27(0.75-2.16)	1.21(0.65-2.27)
Yes	45/26	1.31(0.74-2.32)	1.23(0.62-2.45)	1.09(0.53-2.22)	1.01(0.43-2.39)
<b>ALBI grade</b>					
1	35/22	2.49(1.19-5.22)	2.13(0.88-5.16)	2.33(0.62-8.81)	2.43(0.50-11.8)
2/3	141/101	1.41(1.02-1.95)	1.21(0.85-1.73)	1.16(0.74-1.81)	1.26(0.75-2.12)
<b>FIB-4 index</b>					
≤3.25	88/77	0.80(0.41-1.56)	1.22(0.76-1.96)	1.60(1.03-2.49)	0.60(0.27-1.36)
>3.25	88/48	1.39(0.91-2.14)	1.07(0.65-1.76)	1.47(0.82-2.63)	1.65(0.84-3.24)
<b>HBV hepatitis</b>					
No	17/21	1.41(0.50-3.96)	0.57(0.13-2.49)	0.98(0.18-5.35)	1.04(0.03-42.4)
Yes	70/65	1.54(0.99-2.39)	1.49(0.94-2.37)	1.38(0.71-2.69)	1.58(0.76-3.30)
<b>HCV hepatitis</b>					
No	17/21	1.41(0.50-3.96)	0.57(0.13-2.49)	0.98(0.18-5.35)	1.04(0.03-42.4)
Yes	82/36	1.08(0.68-1.71)	0.91(0.55-1.51)	0.76(0.40-1.43)	0.66(0.32-1.37)
Overall	176/125	1.57(1.17-2.11)	1.29(0.93-1.79)	1.25(0.82-1.91)	1.19(0.73-1.93)

\*Based on Cox proportional hazard regression with adjustment for age, gender, tumor size, tumor number, portal hypertension, albumin level and etiologies of hepatitis.

CSPH: clinically significant portal hypertension; ALBI:albumin-bilirubin; HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona-Clinic Liver Cancer staging system; RFA-TACE: Radiofrequency ablation with or without transcatheter arterial chemoembolization; SR: surgical resection.

**Figure S1.**

